Litcius/Paper detail

Tertiary lymphoid structures as a biomarker in immunotherapy and beyond: Advancing towards clinical application

Xinyu Cui, Xuanyu Gu, Dongyu Li, Patricia Wu, Nan Sun, Chaoqi Zhang, Jie He

2025Cancer Letters30 citationsDOIOpen Access PDF

Abstract

macrophages, with a complex vascular system. TLS formation is governed by lymphotoxin-α1β2, TNF, and chemokines like CCL19, CCL21, and CXCL13, differing from secondary lymphoid organ development in developing later in life at sites of chronic inflammation. Their role in enhancing immune responses, particularly in the context of cancer, makes them a focal point in immunotherapy. This review discusses recent advances in TLS assessment that involves complex gene expression signatures, histological analysis, artificial intelligence, and spatial omics. The presence and maturity of TLS are associated with better outcomes in various cancers, acting as a biomarker for immunotherapy effectiveness. This review explores the structure, formation, and role of TLS in disease prognosis, including their roles in immunotherapy and non-immunotherapy treatments, highlighting a need to develop novel techniques for precise characterization of TLS as well as their significance as predictive biomarkers beyond traditional biomarkers.

Topics & Concepts

BiomarkerImmunotherapyMedicineImmunologyBiologyImmune systemBiochemistryImmunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersImmune Cell Function and Interaction
Tertiary lymphoid structures as a biomarker in immunotherapy and beyond: Advancing towards clinical application | Litcius